X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Emactuzumab
Therapeutic Area: Oncology Product Name: CXD301
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: HEALTHCAPS INDIA LTD.
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 19, 2020
Details:
The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PVNS”), and other indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GDA-201
Therapeutic Area: Oncology Product Name: GDA-201
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Updated data from the ongoing Phase 1 clinical study of GDA-201, an investigational, NK cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma, will be presented in an oral presentation at the American Society of Hematology Annual Meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GDA-201
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2020
Details:
The data showcased the results of updated results from a Phase 1 clinical study of GDA-201 in patients with non-Hodgkin lymphoma and multiple myeloma.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
